TG Therapeutics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Michael S. Weiss
- Full Time Employees
- 399
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3020 Carrington Mill Blvd. Morrisville NY United States of America 27560
- IPO Date
- May 3, 2010
- CIK
- 0001001316
- Website
- tgtherapeutics.com
- Similar Companies
- Business
- TG Therapeutics, Inc. operates as a commercial-stage biopharmaceutical firm, strategically engaged in acquiring, developing, and bringing to market innovative therapies for B-cell mediated autoimmune conditions and various hematologic cancers. The company's primary commercial asset is BRIUMVI (ublituximab-xiiy), a distinct glycoengineered anti-CD20 monoclonal antibody. BRIUMVI has received regulatory approvals in the United States, Europe, and other territories for managing relapsing forms of multiple sclerosis in adults, encompassing clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Its unique value proposition includes its rapid one-hour infusion administration, given twice annually following the initial dose, offering enhanced patient convenience. Beyond its marketed product, the company maintains an active development pipeline featuring several investigational compounds. This includes a subcutaneous formulation of ublituximab, currently in a Phase 3 trial (ENHANCE) for relapsing multiple sclerosis, aimed at further improving patient experience. Other candidates in early-stage clinical development (Phase 1) target B-cell disorders, such as TG-1701, an oral Bruton's tyrosine kinase (BTK) inhibitor, and TG-1801, a bispecific CD47 and CD19 antibody. Additionally, Azer-Cel, an allogeneic CD19 CAR T-cell therapy, is under investigation for B-cell malignancies. TG Therapeutics has reported robust financial performance, with significant revenue growth driven by BRIUMVI sales, and has recently completed and authorized substantial share repurchase programs. The firm has also secured a national contract with the U.S. Department of Veterans Affairs for BRIUMVI as a preferred treatment for relapsing multiple sclerosis. Collaborative agreements, such as the ex-U.S. commercialization partnership with Neuraxpharm Group for BRIUMVI, underscore its strategic approach to expanding market reach. Incorporated in 1993, TG Therapeutics, Inc. is headquartered in Morrisville, North Carolina.
Bank of America Corp DE Purchases 610,195 Shares of TG Therapeutics, Inc. $TGTX
Assenagon Asset Management S.A. Lowers Stock Position in TG Therapeutics, Inc. $TGTX
Brokerages Set TG Therapeutics, Inc. (NASDAQ:TGTX) Price Target at $63.00
Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Empowered Funds LLC Increases Stake in TG Therapeutics, Inc. $TGTX
TG Therapeutics: Why I'm Staying Long After The Q2 Selloff
TGTX Q2 Earnings Lag, Sales Rise Y/Y, 2026 View Raised, Stock Down
TG Therapeutics, Inc. (TGTX) Q2 2026 Earnings Call Transcript
Here's What Key Metrics Tell Us About TG Therapeutics (TGTX) Q2 Earnings
TG Therapeutics Q2 Earnings Call Highlights
TG Therapeutics (TGTX) Misses Q2 Earnings Estimates
TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance
TG Therapeutics to Host Conference Call on Second Quarter 2026 Financial Results and Business Update
TG Therapeutics (TGTX) to Report Q2 Results: Wall Street Expects Earnings Growth
Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm
2 Fast-Growing Pharmaceutical Stocks to Buy Now
TG Therapeutics Begins Phase II Study With Briumvi in Schizophrenia
TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia